TRINITY BIOTECH PLC
No enriched coverage for $TRIB in the last 7 days.
No SEC Form 4 filings for $TRIB in the last 30 days.
See all $TRIB insider activity →Trinity Biotech’s Trinovium unit said it is collaborating with Echelon Data Centres to develop liquid cooling solutions for AI and high-density computing, using Trinovium’s ultra-high-purity fluids and sensing. Echelon has 700 MW under development and 1.4 GW secured. Trinity also reported $7.0M new funding from Perceptive Advisors and Q ended June 30, 2026 revenue of about $10.5M.
Trinity Biotech plc (Nasdaq: TRIB) said Perceptive Advisors will provide about $7.0 million in additional funding, including $2.5 million in new debt and about $4.5 million in capitalized interest, to support initiatives such as CGM+ and Trinovium. The company also confirmed it regained Nasdaq minimum bid price compliance. Preliminary Q2 2026 revenue was about $10.5 million.
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
Recent TRIB coverage spans financial news, technology and corporate actions.
The deal is a strategic product-development step that could support future commercialization, but it is not yet a quantified revenue contract.
The $7.0M financing plus Nasdaq compliance reduces near-term liquidity and delisting risk, which can support the stock while investors watch execution on CGM+ and Trinovium.
Reverse split compliance action plus Q2-driven catalyst likely supports near-term momentum, but can also raise dilution/volatility concerns.
Positive clinical validation of CGM+ multi-sensor false-low detection could improve differentiation and partner interest ahead of pivotal/regulatory steps.
Termination of the SEPA removes a potential equity-funding backstop, signaling a shift in financing strategy and potentially increasing near-term capital planning risk.
alphai scores every news story that mentions TRIB with an AI model for sentiment and relevance, and aggregates insider trades from TRINITY BIOTECH PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Trinity Biotech’s Trinovium unit said it is collaborating with Echelon Data Centres to develop liquid cooling solutions for AI and high-density computing, using Trinovium’s ultra-high-purity fluids and sensing. Echelon has 700 MW under development and 1.4 GW secured. Trinity also reported $7.0M new funding from Perceptive Advisors and Q ended June 30, 2026 revenue of about $10.5M.
4 min readTrinity Biotech plc (Nasdaq: TRIB) said Perceptive Advisors will provide about $7.0 million in additional funding, including $2.5 million in new debt and about $4.5 million in capitalized interest, to support initiatives such as CGM+ and Trinovium. The company also confirmed it regained Nasdaq minimum bid price compliance. Preliminary Q2 2026 revenue was about $10.5 million.
3 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readTrinity Biotech plc (Nasdaq: TRIB) reported clinical results for its CGM+ multi-sensor wearable, analyzing ~5,000 hours of device wear data from insulin-dependent people with diabetes in a pre-pivotal trial completed in Q2 2026. The company says an algorithm distinguishes nocturnal compression-related false low glucose alarms from true lows, addressing a limitation of glucose-only CGMs.
5 min readTrinity Biotech plc (Nasdaq: TRIB) said it notified YA II PN, LTD., an affiliate of Yorkville Advisors Global, that it is terminating its Standby Equity Purchase Agreement (SEPA) equity line of credit. The company stated it will not use the SEPA further and cited its current financing strategy.
2 min readTrinity Biotech (NASDAQ: TRIB) launched Trinovium, a new subsidiary targeting advanced liquid cooling fluids and “fluid intelligence” systems for AI data centers and high-performance computing. The company said it will use existing US/EU manufacturing capacity and its high-purity fluid and analytical technologies. Trinity cited MarketsandMarkets projecting the liquid cooling market rising from $4B (2026) to $27B (2033).
4 min readTrinity Biotech (TRIB) updated on Q4 2025 trading and business progress, projecting Q4 2025 revenue of $11.5M–$12.5M, a decrease from Q4 2024 due to HIV testing market disruptions and manufacturing transitions. Despite this, the company highlighted positive developments such as regulatory approval to outsource Uni-Gold manufacturing, growing demand for its rapid HIV tests, IFCC Gold classification for its HbA1c solution, and ongoing development of new products like CGM+, EpiCapture, and PrePsia. The market reacted positively, with TRIB stock gaining 5.10% following the news, reflecting investor confidence in the company's long-term transformation strategy.
4 min readThis article details the stocks making significant moves in Tuesday's midday trading. Novo Nordisk (NVO) is up after FDA approval for its Wegovy pill, Trinity Biotech (TRIB) rose on a large order for its HIV diagnostic test, and VisionWave (VWAV) increased due to a new patent. Conversely, Starfighters Space (FJET) experienced a drop after a massive rally, and ServiceNow (NOW) fell following its acquisition of a cybersecurity startup.
4 min readDUBLIN, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( NASDAQ:TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization ( WHO ) approval for ...
3 min readStrategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation ...
3 min read
